

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/786,810
Filing Date	02-25-2004
First Named Inventor	JESUS BENAVIDES, ET AL
Group Art Unit	
Examiner Name	
Attorney Docket Number	ST01023 - US - CNT

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
YC		BROTCHIE, J. M., The Cannabinoid Receptor Antagonist SR141716A Reduces L-DOPA-Induced Dyskinesia in the MPTP-Treated Primate Model of Parkinson's Disease, British Journal of Pharmacology (1998, Volume 123, pp. 66P)	
		CLARA SANUDO-PENA et al., A Novel Neurotransmitter System Involved in the Control of Motor Behavior by the Basal Ganglia, Ann. New York Academy of Sciences, (1998, Volume 860, pp. 475-478)	
		JUSTIN P. MESCHLER et al., D2, but not D1 Dopamine Receptor Agonists Potentiate Cannabinoid-Induced Sedation in Nonhuman Primates 1,2 Journal of Pharmacology And Experimental Therapeutics, (2000, Volume 292, Issue 3, pp. 952-959)	
		VINCENZO DI MARZO et al., Enhanced Levels of Endogenous Cannabinoids in the Globus Pallidus are Associated with a Reduction in Movement in an animal model of Parkinson's Disease, FASEB Journal (2000, Volume 14, Issue 10, pp. 1432-1438)	

Examiner
Signature

Jay Chong

Date
Considered

2/14/06

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.